title: Success rate and patients' satisfaction following intradetrusor dysport injection in patients with detrusor overactivity: a comparative study of idiopathic and neurogenic types of detrusor overactivity.
abstract: OBJECTIVE
  To evaluate the efficacy of intradetrusor Dysport (a type of botulinum toxin type A) injection in patients with idiopathic or neurogenic detrusor overactivity, who were refractory to antimuscarinic drugs, and to compare the efficacy of Dysport injection in both groups.
  
  
  METHODS
  Twelve patients with neurogenic detrusor overactivity (NDO) and 18 patients with idiopathic detrusor overactivity (IDO) participated in this study. All the patients received intravesical injection of 500 units of Dysport. They were followed up for 3 months after injection with maximum cystometric capacity, maximum detrusor filling pressure, and number of catheterization or pad usage.
  
  
  RESULTS
  After 3 months, the mean maximum cystometric capacity increased from 109.36 ± 24.11 mL to 266.81 ± 97.18 mL (P = .000) in the NDO group and from 192.24 ± 36.21 mL to 272.61 ± 63.37 mL (P = .000) in the IDO group. The mean maximum detrusor filling pressure decreased from 48.14 ± 26.51 cmH2O to 28.91 ± 9.01 cmH2O (P = .005) in the NDO group and from 39.22 ± 9.92 cmH2O to 29.64 ± 10.14 cmH2O (P = .003) in the IDO group.
  
  
  CONCLUSIONS
  Intradetrusor Dysport injection improved urodynamic parameters and quality of life (QoL) in both groups significantly. We did not find significant difference in QoL or urodynamic parameters between both groups.
authors.affiliation: Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Saeed
authors.initials: S
authors.lastname: Shakeri
authors.affiliation: Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Reza
authors.initials: R
authors.lastname: Mohammadian
authors.affiliation: Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Aminsharifi
authors.affiliation: Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Ali
authors.initials: A
authors.lastname: Ariafar
authors.affiliation: Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Jalal
authors.initials: J
authors.lastname: Vaghedashti
authors.affiliation: Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Yazdani
authors.affiliation: Trauma research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Yadollahi
authors.affiliation: Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Vahid
authors.initials: V
authors.lastname: Emadmarvasti
authors.affiliation: Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Amir
authors.initials: A
authors.lastname: Baharikhoob
mesh_terms: D000283:Administration, Intravesical; D000293:Adolescent; D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D012074:Remission Induction; D001750:Urinary Bladder, Neurogenic / Q000150:complications; D053201:Urinary Bladder, Overactive / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D055815:Young Adult
chemical_list: D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA